Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMBINED THERAPY WITH ZIDOVUDINE, RECOMBINANT GRANULOCYTE-COLONY-STIMULATING FACTORS AND ERYTHROPOIETIN IN ASYMPTOMATIC HIV PATIENTS
Autore:
PERRELLA O; FINELLI E; PERRELLA A; TARTAGLIA G; SCOGNAMIGLIO P; SCALERA G;
Indirizzi:
VIA E A MARIO 35 I-80131 NAPLES ITALY HOSP D COTUGNO,DEPT INFECT DIS 3 NAPLES ITALY
Titolo Testata:
Journal of chemotherapy
fascicolo: 1, volume: 8, anno: 1996,
pagine: 63 - 66
SICI:
1120-009X(1996)8:1<63:CTWZRG>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; AZIDOTHYMIDINE AZT; VIRUS INFECTION; DOUBLE-BLIND; TOXICITY;
Keywords:
ZIDOVUDINE; RECOMBINANT GRANULOCYTE-COLONY STIMULATING FACTORS; ERYTHROPOIETIN; HUMAN IMMUNODEFICIENCY VIRUS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
12
Recensione:
Indirizzi per estratti:
Citazione:
O. Perrella et al., "COMBINED THERAPY WITH ZIDOVUDINE, RECOMBINANT GRANULOCYTE-COLONY-STIMULATING FACTORS AND ERYTHROPOIETIN IN ASYMPTOMATIC HIV PATIENTS", Journal of chemotherapy, 8(1), 1996, pp. 63-66

Abstract

The aim of this randomized, comparative, double-blind study was to determine the efficacy of zidovudine (ZVD) either alone or in combination with recombinant granulocyte-colony stimulating factors (rG-CSF) anderythropoietin (Epo) in asymptomatic HIV-infected subjects with a CD4 cell count < 500/mm(3), classified as CDC II stage. We recruited 20 HIV Ab+ asymptomatic patients who were randomized into two groups : A and B. Group A was treated with ZVD at the dosage of 500 mg daily in combination with rG-CSF (10 mu g/Kg/biweekly) and Epo (50 IU/Kg/biweekly). Group B was treated with ZVD (500 mg/day) alone. The primary end-point was progression to an AIDS-defining event and the secondary end-point included changes in the CD4+ cell count, p24 Ag status, beta-2-microglobulin, and ferritin levels. The patients of Group A showed no significant changes in transaminase, ferritin and beta-2-microglobulin levels while CD4 cells, Hb and neutrophil levels increased significantly compared to Group B (p < 0.001) and baseline values (p < 0.05). Conversely, 5 patients in Group B showed a significant decrease in CD4 cells (p < 0.01), Hb and neutrophil levels (p < 0.01) compared to baseline values, while beta-2-microglobulin increased (p < 0.05) compared to initial values. Our preliminary study may indicate that the combination of zidovudine with these hematopoietic growth factors could reduce the possibility of virus-related hematologic toxicity and could be moreefficacious than zidovudine alone in prolonged therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 12:08:54